AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
AAPL   322.09 (+0.07%)
MSFT   183.05 (+0.12%)
FB   230.17 (-0.75%)
AMZN   2,468.95 (-0.08%)
NVDA   350.55 (-0.48%)
BABA   209.85 (+1.59%)
GE   6.94 (+2.66%)
TSLA   899.42 (+0.15%)
ACB   14.13 (+0.21%)
F   5.96 (+1.53%)
GILD   73.95 (-1.61%)
DIS   118.86 (+0.08%)
BAC   25.03 (+1.71%)
Log in

NASDAQ:CDMOAvid Bioservices Stock Price, Forecast & News

$6.15
+0.20 (+3.36 %)
(As of 06/2/2020 09:34 AM ET)
Add
Compare
Today's Range
$6.05
Now: $6.15
$6.16
50-Day Range
$4.11
MA: $5.48
$6.42
52-Week Range
$3.02
Now: $6.15
$8.38
Volume5,943 shs
Average Volume315,354 shs
Market Capitalization$347.35 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and Current Good Manufacturing Practices (CGMP) commercial manufacturing services focused on biopharmaceutical products derived from mammalian cell culture for biotechnology and pharmaceutical companies. The company produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and offers services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory submission and support. It also provides various process development services, such as cell line development and optimization, cell culture and feed optimization, analytical methods development, and product characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Read More
Avid Bioservices logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.17 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDMO
CUSIPN/A
Phone714-508-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.60 million
Book Value$0.95 per share

Profitability

Net Income$-4,220,000.00

Miscellaneous

Employees211
Market Cap$347.35 million
Next Earnings Date6/25/2020 (Estimated)
OptionableOptionable

Receive CDMO News and Ratings via Email

Sign-up to receive the latest news and ratings for CDMO and its competitors with MarketBeat's FREE daily newsletter.

Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions

How has Avid Bioservices' stock been impacted by COVID-19 (Coronavirus)?

Avid Bioservices' stock was trading at $4.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CDMO stock has increased by 33.9% and is now trading at $6.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Avid Bioservices?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avid Bioservices.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Thursday, June 25th 2020. View our earnings forecast for Avid Bioservices.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices Inc (NASDAQ:CDMO) released its quarterly earnings data on Tuesday, March, 10th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The biopharmaceutical company had revenue of $13.59 million for the quarter, compared to analyst estimates of $16.80 million. Avid Bioservices had a negative net margin of 8.35% and a negative return on equity of 10.98%. View Avid Bioservices' earnings history.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on the morning of Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, March, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55-59 million, compared to the consensus revenue estimate of $67.03 million.

What price target have analysts set for CDMO?

5 analysts have issued 1-year price targets for Avid Bioservices' stock. Their forecasts range from $7.50 to $11.00. On average, they expect Avid Bioservices' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 57.3% from the stock's current price. View analysts' price targets for Avid Bioservices.

Has Avid Bioservices been receiving favorable news coverage?

Press coverage about CDMO stock has been trending very positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avid Bioservices earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutAvid Bioservices.

Who are some of Avid Bioservices' key competitors?

What other stocks do shareholders of Avid Bioservices own?

Who are Avid Bioservices' key executives?

Avid Bioservices' management team includes the following people:
  • Mr. Richard B. Hancock, Interim Pres, CEO & Director (Age 61, Pay $80.08k)
  • Mr. Daniel R. Hart, Chief Financial Officer (Age 47, Pay $477.95k)
  • Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $485.05k)
  • Mr. Richard Richieri, Chief Operations Officer (Age 55)
  • Ms. Lorna Larson, Sr. Director of HR

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.87%), AltraVue Capital LLC (3.45%), Sargent Investment Group LLC (2.06%), State Street Corp (1.84%), Geode Capital Management LLC (1.31%) and Silvercrest Asset Management Group LLC (1.30%). Company insiders that own Avid Bioservices stock include Daniel Ryan Hart, Joel Mccomb, Joseph Carleone, Mark R Bamforth, Patrick D Walsh and Richard B Hancock. View institutional ownership trends for Avid Bioservices.

Which institutional investors are selling Avid Bioservices stock?

CDMO stock was sold by a variety of institutional investors in the last quarter, including AltraVue Capital LLC, Morgan Stanley, Wells Fargo & Company MN, BlackRock Inc., UBS Group AG, Deutsche Bank AG, Essex Investment Management Co. LLC, and Quinn Opportunity Partners LLC. View insider buying and selling activity for Avid Bioservices.

Which institutional investors are buying Avid Bioservices stock?

CDMO stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Sargent Investment Group LLC, Silvercrest Asset Management Group LLC, Nuveen Asset Management LLC, ClariVest Asset Management LLC, GSA Capital Partners LLP, Los Angeles Capital Management & Equity Research Inc., and Driehaus Capital Management LLC. Company insiders that have bought Avid Bioservices stock in the last two years include Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Patrick D Walsh, and Richard B Hancock. View insider buying and selling activity for Avid Bioservices.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $6.04.

How big of a company is Avid Bioservices?

Avid Bioservices has a market capitalization of $341.14 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 211 workers across the globe.

What is Avid Bioservices' official website?

The official website for Avid Bioservices is www.avidbio.com.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.